Endocrine Fellows Series: 2018 Osteoporosis and Metabolic Bone Diseases

Wednesday, August 1, 2018 Thursday, August 2, 2018
Hotel Santa Fe

The annual Endocrine Fellows Series: Osteoporosis and Metabolic Bone Diseases is a CME-certified conference of pediatric and adult endocrine fellows held in conjunction with the Santa Fe Bone Symposium (August 3-4,2018) in Santa Fe, New Mexico. Faculty members present clinical content that incorporate practice guidelines, newly reported research findings, preclinical research and clinical practice patterns from across the field of bone and calcium disorders. In addition, group discussion sessions provide case-based practical strategies on the diagnosis and treatment of patients with osteoporosis and metabolic bone diseases. In addition to the small group setting, which allows fellows to interact with the expert faculty, one of the unique components of Osteo Fellows is the abstract presentation. Select fellows are given the opportunity to present their research at Osteo Fellows and at the Santa Fe Bone Symposium.

This activity is supported by educational grants from Amgen Inc.; Radius Health, Inc.; and Ultragenyx.

Target Audience

This continuing medical education activity should be of substantial interest to first, second, or third-year endocrine fellows.

Learning Objectives

Upon completion of this educational activity, participants will be better able to:

  • Describe the pathophysiology of osteoporosis
  • Discuss with patients the risk factors for low bone mineral density and fracture risk
  • Describe the epidemiology of osteoporosis
  • Assess bone strength in clinical practice
  • Evaluate fracture risks in different patient populations
  • Perform diagnostic evaluation of the osteoporotic patient
  • Compare the various techniques used to measure bone density, including the pitfalls of each
  • Assess fracture risk in diverse patients
  • Access the fracture risk of various types of patients, including adults and children
  • Interpret the treatment guidelines to provide the proper care to patients
  • Recognize and assess low bone mass in children
  • Examine the pitfalls of evaluating low bone mass in pediatric patients
  • Evaluate fracture risk in the pediatric population
  • Identify causes of  low bone mass other than osteoporosis
  • Evaluate bone health in patients with other medical problems
  • Identify patients with unrecognized vertebral fractures
  • Describe the role of Calcium, Vitamin D and exercise in skeletal health
  • Select appropriate lifestyle and nutritional interventions to treat patients with osteoporosis
  • Outline existing antiresorptive therapies used to treat patients with osteoporosis
  • Recognize how antiresorptive therapies may reduce fracture risk
  • Identify key considerations for determining whether or not a patient should be a candidate for antiresorptive therapies.
  • Determine when to start and stop treatment with bisphosphonates
  • Recognize situations when the use of a RANKL inhibitor is the best treatment option
  • Outline existing anabolic therapy and combination therapy used to treat patients with osteoporosis
  • Recognize how anabolic therapy and combination therapy may reduce fracture risk
  • Identify key considerations for determining whether or not a patient should be a candidate for anabolic and combination therapies
  • Identify risk factors for osteoporosis in men
  • Evaluate indications for osteoporosis therapy in men
  • Diagnose and manage male patients with osteoporosis
  • Identify, evaluate and develop treatment options for children and adolescents with osteoporosis
  • Monitor and manage osteoporosis therapy in children and adolescents
  • Identify patients with glucocorticoid-induced bone loss
  • Implement and manage appropriate treatment of osteoporosis in patients with glucorticoid-induced bone loss
  • Describe and discuss the epidemiology of Paget’s disease
  • Identify patients with Paget’s disease
  • Evaluate best treatment strategies for the management of patients with Paget’s disease
  • Describe the differential diagnosis of osteomalacia
  • Discuss the treatment options available to patients with osteomalacia
  • Describe the pathophysiology of primary hyperparathyroidism
  • Identify patients with osteoporosis who are best candidates for PTH therapy
  • Evaluate therapeutic strategies for the management of hyperparathyroidism
  • Identify and properly evaluate patients for hypoparathyroidism
  • Determine the correct use of thiazide diuretics, vitamin D metabolites, and rhPTH for difficult cases of hypoparathyroidism
  • Understand the mechanism and utility of emerging therapies in the management of hypoparathyroidism
  • Identify and manage some of the nosological entities that endocrinologists are called upon for diagnosis and treatment (i.e., normocalcemic hyperparathyroidism, Paget’s disease, adult forms of osteogenesis imperfecta, fibrous dysplasia of bone, etc.)
  • Discuss the genetic underpinnings and pathophysiology of hypophosphatasia
  • Recognize skeletal and non-skeletal sequelae of hypophosphatasia
  • Identify and discuss future imaging techniques for managing osteoporosis
  • Identify and discuss future therapeutic options for managing osteoporosis in the adult and adolescent population

Additional Information

Target Audience: 
Fellow
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Topic Area: 
Bone and Calciotropic Hormones
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Activity summary
Available credit: 
  • 14.25 AMA PRA Category 1 Credits
  • 14.25 CME Certificate of Participation
Course opens: 
03/28/2018
Course expires: 
10/31/2018
Rating: 
5

Program Director
Michael R McClung, MD – Oregon Osteoporosis Center

Disclosure Policy

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

Catherine Gordon, MD, MS: Member, Data and Safety Monitoring Board, Janssen Pharmaceuticals and Lilly Pharmaceuticals
Michael McClung, MD: Consultant and Speaker, Amgen, Inc., Radius Health, Inc.

The following faculty reported no relevant financial relationships: John Bilezikian, MD, PhD; Mary Bouxsein, PhD; and Susan Greenspan, MD

The Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

 

Available Credit

  • 14.25 AMA PRA Category 1 Credits
  • 14.25 CME Certificate of Participation

Accreditation Period

Course opens: 
03/28/2018
Course expires: 
10/31/2018